Algert Global LLC Trims Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Algert Global LLC trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 17.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 127,340 shares of the medical equipment provider's stock after selling 26,207 shares during the period. Algert Global LLC owned approximately 0.18% of Lantheus worth $10,224,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in shares of Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 247 shares during the period. GAMMA Investing LLC increased its position in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 208 shares during the last quarter. Fidelis Capital Partners LLC bought a new position in Lantheus in the first quarter valued at about $34,000. FinTrust Capital Advisors LLC boosted its position in Lantheus by 53.6% in the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 232 shares during the last quarter. Finally, Nkcfo LLC bought a new position in Lantheus in the second quarter worth approximately $47,000. Institutional investors own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LNTH. Leerink Partners lifted their target price on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. JMP Securities decreased their target price on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. Truist Financial dropped their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Finally, Redburn Atlantic assumed coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Insiders Place Their Bets

In other news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the business's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the sale, the chief accounting officer now owns 62,216 shares of the company's stock, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock valued at $3,922,001 in the last three months. Corporate insiders own 1.50% of the company's stock.

Lantheus Price Performance

LNTH stock traded up $2.93 during mid-day trading on Friday, hitting $107.36. The company had a trading volume of 673,088 shares, compared to its average volume of 1,012,192. The company has a 50-day moving average price of $104.45 and a 200 day moving average price of $86.04. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a market capitalization of $7.44 billion, a price-to-earnings ratio of 16.39 and a beta of 0.50. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business's quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.40 EPS. On average, research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.